Sector X · 6 chokepoints · 18 names

Healthcare

The GLP-1 & Bio Supply Chain — Peptides, Bioprocessing & Diagnostics

Picking the next blockbuster drug is a coin flip. Picking the companies that supply every drugmaker is not. Right now the biggest pharma supply crunch in history is happening around GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound). Per Fortune Business Insights, the global GLP-1 receptor agonist market was $62.8B in 2025, projected $73.4B in 2026. The patients all want a Novo or Lilly product — but behind every blockbuster injection is a chain of 5–8 specialized vendors: peptide CDMO → fill-finish → glass vial or syringe → rubber stopper → distribution.

Bachem (Swiss) makes the peptide. Stevanato (Italian) makes the special glass. West Pharmaceutical (US) makes the rubber stopper. If any one of them has a hiccup, Ozempic doesn't ship. Then there's the broader life-sciences supply chain — bioprocessing, sequencing, diagnostics — which is recovering from a 2024 destocking and now compounding again. Most of these names are oligopolies with multi-year regulatory qualification cycles. Hard to disrupt.

Sources

Fortune Business Insights, Precedence Research · 2025–2026

The 6 chokepoints

pick one to see its names

Choke 01

The Peptide CDMOs — Making the GLP-1 Molecules

Solid-Phase Peptide Synthesis · GLP-1 APIs · 88+ Approved Peptide Drugs

Every Ozempic shot started its life as a chain of 30+ amino acids assembled in a Swiss CDMO. Two companies dominate. They are sold out for years.

GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are peptides — short chains of amino acids manufactured by linking 30–40 building blocks together in a process called solid-phase peptide synthesis (SPPS). Each coupling cycle takes hours. The chemistry, scaled to multi-ton production, is dominated by a handful of contract development and manufacturing organizations (CDMOs). Bachem (Switzerland) is #1. PolyPeptide (Switzerland) is #2. Lonza is a much larger generalist CDMO with peptide capability. All are sold out through multi-year contracts.

Why this is a chokepoint

Capacity expansion takes 3–5 years from groundbreaking to FDA approval of the new line. Demand is exploding. Even with Novo Nordisk and Eli Lilly building in-house capacity, the merchant peptide CDMO market is sold out for years.

Loading live prices… 0/3

BANB.SW

Bachem Holding

not US-tradable

#1 global peptide CDMO. Makes the API for Wegovy, Zepbound, and 88+ approved peptide drugs plus 267 in late-stage trials.

Swiss CDMO that develops and manufactures peptides (and oligonucleotides) at GMP scale for pharma customers . The single most important supplier in the GLP-1 supply chain. Largest commercial-scale third-party peptide CDMO globally. Each GLP-1 peptide requires 30–40 SPPS coupling cycles. Capacity expansion underway at Bubendorf "Building K," Vista CA (~1 metric ton/year), St Helens UK, and a new Sisseln site.

snapshotView detail →

PPGN.SW

PolyPeptide Group

not US-tradable

#2 global peptide CDMO. €100M Malmö SPPS expansion underway.

Swiss #2 peptide CDMO behind Bachem. Smaller, more turnaround-focused. €100M Malmö SPPS expansion underway. Higher beta way to play the same GLP-1 thesis with more upside if execution holds — but also more downside if customers concentrate orders at Bachem.

snapshotView detail →

LONN.SW

Lonza Group

not US-tradable

Largest CDMO globally — small molecules, biologics, cell/gene, peptides. Broader exposure than pure-play peptide names.

Largest CDMO globally — handles small molecules, biologics, cell/gene therapy, and peptides for pharma customers. FY26 sales growth confirmed at 11–12%. Lower-beta diversified way to own the picks-and-shovels theme without single-peptide concentration. Less GLP-1 leverage but more growth durability.

snapshotView detail →

Open full chokepoint →